These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4084461)

  • 1. Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe).
    Soria J; Soria C; Hedner U; Nilsson IM; Bergqvist D; Samama M
    Br J Haematol; 1985 Dec; 61(4):727-38. PubMed ID: 4084461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen Adelaide: a familial hypodysfibrinogenaemia associated with abnormal alpha chains.
    Exner T; Barber S; Sage RE; Kronenberg H
    Br J Haematol; 1984 Jan; 56(1):95-106. PubMed ID: 6704329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
    Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
    Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
    Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
    Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfibrinogenaemia associated with a defect in the aggregation of the fibrin monomers (Almeria I fibrinogen). A preliminary study.
    Vila V; Regañon E; Fernandez-Pavon A; Aznar J
    Scand J Haematol; 1984 Nov; 33(5):460-5. PubMed ID: 6515329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hereditary dysfibrinogenemia: fibrinogen Awaji.
    Matsuo T; Okuno S; Mukaida T; Ueshima S; Okada K; Matsuo O
    Haemostasis; 1987; 17(1-2):89-97. PubMed ID: 3596361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA.
    Engesser L; Koopman J; de Munk G; Haverkate F; Nováková I; Verheijen JH; Briët E; Brommer EJ
    Thromb Haemost; 1988 Aug; 60(1):113-20. PubMed ID: 3142089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Lima. A new dysfibrinogenaemia with a high-molecular-weight alpha-chain and effective polymerization.
    Arocha-Piñango CL; Rodriguez S; Nagy H; Perez Requejo JL
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):561-5. PubMed ID: 2133234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
    Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
    Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Life-long hemorrhagic diathesis in a young man with unclottable global coagulation tests--congenital afibrinogenemia].
    Peter K; Furlan M; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):516-8. PubMed ID: 10517123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Irvine: a qualitatively abnormal fibrinogen associated with the predisposition to recurrent visceral and peripheral venous thrombosis.
    Lehmer RR; Elias AN; Capdeville MJ; Brown DR; Branson HE
    J Natl Med Assoc; 1985 Jul; 77(7):561-5. PubMed ID: 4046054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.
    Matsuda M; Baba M; Morimoto K; Nakamikawa C
    J Clin Invest; 1983 Sep; 72(3):1034-41. PubMed ID: 6886002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of Fibrinogen and Thrombin Time (TT).
    Undas A
    Methods Mol Biol; 2017; 1646():105-110. PubMed ID: 28804822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital hypodysfibrinogenaemia (Fibrinogen Des Moines) due to a gamma320Asp deletion at the Ca2+ binding site.
    Brennan SO; Davis RL; Mosesson MW; Hernandez I; Lowen R; Alexander SJ
    Thromb Haemost; 2007 Aug; 98(2):467-9. PubMed ID: 17721633
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation.
    Rodeghiero F; Castaman GC; Dal Belin Peruffo A; Dini E; Galletti A; Barone E; Gastaldi G
    Thromb Haemost; 1987 Jun; 57(3):252-8. PubMed ID: 2958952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
    Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two novel mutations in the fibrinogen γ nodule.
    Kotlín R; Pastva O; Stikarová J; Hlaváčková A; Suttnar J; Chrastinová L; Riedel T; Salaj P; Dyr JE
    Thromb Res; 2014 Oct; 134(4):901-8. PubMed ID: 25074738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Unexpectedly prolonged thrombin time].
    Barth A; Furlan M; Lämmle B
    Schweiz Med Wochenschr; 1993 Mar; 123(12):523-9. PubMed ID: 8475358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.
    Haverkate F; Samama M
    Thromb Haemost; 1995 Jan; 73(1):151-61. PubMed ID: 7740487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A kinetic method for characterization of heterogenous fibrinogen and its application to fibrinogen Grand Rapids, a congenital dysfibrinogenemia.
    Higgins DL; Lewis SD; Penner JA; Shafer JA
    Thromb Haemost; 1982 Oct; 48(2):182-6. PubMed ID: 6217579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.